PhytoMedical’s compound for difficult-to-treat human brain cancer
shows case of significantly enhanced chemotherapeutic effects on human
glioblastoma xenografts
...
#28: PYTO PhytoMedical’s Patented Anti-Cancer Compound Eradicates Tumor in Successful In-Vivo Tests against Human Brain Cancer PhytoMedical’s compound for difficult-to-treat human brain cancer reveals case of “tumor cured”; demonstrates prolonged survival rat
PhytoMedical’s Patented Anti-Cancer Compound Eradicates Tumor in Successful In-Vivo Tests against Human Brain Cancer
PhytoMedical’s compound for difficult-to-treat human brain cancer
...
PhytoMedical’s anti-cancer compounds
shown to successfully kill cells from multiple human cancers; Company
initiates next phase of product development
...
New tests show PhytoMedical’s ‘next-generation’
compounds kill colon cancer cells; retain key ability to kill
glioblastoma cells (brain cancer), similar to Company’s
...
Patented anticancer compounds demonstrate special ability to kill
multiple human cancer cells; success against often-terminal lung cancer,
and brain cancer, an extremely...
Novel class of antitumor compounds are designed to bind to DNA and kill cancer cells; previously demonstrated ability to kill brain cancer cells, an extremely resistant and often fatal...
Beacon Research Issues TraderNotes on XSNX, NOEC, PYTO, CELG, AERO
DALLAS, Jan. 7 /PRNewswire/ --.
Investors can view all of the daily trading notes for free by visiting:...
Novel Class of Patented Anti-Cancer Compounds Demonstrates
Significant Ability to Kill Human Glioblastoma (Brain) Cancer Cells, an
Extremely Resistant and Often Fatal Strain of...
Novel Class of Anti-Cancer Agents Block Cancer Cell DNA Replication
Through Process Called “Bis-Intercalation,”
Which Inhibits Cancer Cell Growth
PhytoMedical...
PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced the addition of Dr. Mark A. Bossie, a specialist in the identification,...
PRINCETON, N.J.--(BUSINESS WIRE)--As part of the Company’s ongoing efforts to further the development of its synthesized analogues for type-2 diabetes, PhytoMedical Technologies,...
PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6), focused on research, development and commercialization of pharmaceutical products, today...
PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6) today announced
that it is finalizing the developmental transition of its new class of ...
PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6) today announced
plans to expedite the development of its new class of cinnamon-derived...
PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6) announced today
the addition of pharmacology researcher and drug discovery and
development...
